Has Raza Shah received payments from drug or device companies?

Yes. Drug and device makers reported $2,005 in general payments to Raza Shah across 95 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Raza Shah did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Raza Shah come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Raza Shah

Pulmonary Disease · Orlando, FLNPI 1013925320

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by GSK at 25.8% of the total. Reporting peaked in 2019 at $1,405 and has fallen 90.7% since, to $130 in 2021. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.

$2,005in general payments, 2019–2025

Across 95 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$517
Boehringer Ingelheim$299
Mylan Specialty L.p.$244
Pfizer$135
Regeneron Healthcare Solutions, Inc.$117
Abbott$110
plus $582 from 13 others

What the payments were for

Food & beverage$1,89094%
Education$1156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	32	$517
Boehringer Ingelheim	15	$299
Mylan Specialty L.p.	8	$244
Pfizer	2	$135
Regeneron Healthcare Solutions, Inc.	6	$117
Abbott	1	$110
Genentech USA, Inc.	5	$101
AstraZeneca	6	$92
Insmed, Inc.	2	$87
Takeda Pharmaceuticals U.S.A., Inc.	3	$60
Philips North America LLC	4	$58
Grifols USA, LLC	3	$40
Electromed, Inc.	2	$32
Sunovion Pharmaceuticals Inc.	1	$24
Teva Pharmaceuticals USA, Inc.	1	$19
Sanofi	1	$19
Bayer	1	$17
Shire North American Group Inc	1	$17
Alk-abello, Inc	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,005 in reported general payments places this provider in the 40th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida →

Other pulmonary disease in Orlando

Ali JiwaniOrlando$859K
Junaid MalikOrlando$429K
Franck RahaghiWeston$1.2M
Michael OttEglin Afb$909K
Anas HadehWeston$800K
Jennifer FultonJacksonville$665K
Ricardo Restrepo-JaramilloTampa$555K
Mark RumbakTampa$528K
Jose Soto SotoJacksonville$504K
Javier Perez FernandezMiami$496K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →